Caliper Life Sciences this week launched the LabChip Dx system for use in the development of molecular diagnostic tests.
The LabChip Dx platform enables the simultaneous analysis of up to ten different analytes in a single sample, the company said.
The system uses Caliper's microfluidic technology, which allows users to analyze large quantities of multiplex samples, as well as avoid additional purification and dilution steps that are usually necessary with diagnostic PCR products.
"The market has been evolving to run multiple tests simultaneously, and our LabChip Dx product is intended to address this trend," Kevin Hrusovsky, Caliper Life Sciences CEO, said in a statement.
According to Hrusovsky, the launch of the diagnostics system marks the first step in the company's overall strategy to enter the molecular diagnostics market.
"We are currently seeking partners with unique molecular diagnostic content for validation and clearance by regulatory agencies," Hrusovsky said. "Long term, we intend to combine our molecular diagnostics competencies with our recently acquired multiplex tissue imaging technology to enter the emerging field of companion diagnostics."
This week, the company announced its first such deal under that strategy — an alliance with Korean molecular diagnostics firm Seegene that will enable Seegene's SeePlex multiplex diagnostic assays to run on the LabChip Dx platform.
The firms will co-market Caliper's LabChip Dx platform and Seegene's complete line of multiplex diagnostic content and will also work together to expand the number of diagnostic tests available on the platform.
Seegene's network of distributors will market and distribute the Seeplex assays outside of the US in a preferred partnership for use with the LabChip Dx, the firms said.
Among Seegene's assays are multiplex tests for human papillomavirus, respiratory viruses, and vancomycin-resistant Enterococcus.